Comparative Pharmacology
Head-to-head clinical analysis: ANASTROZOLE versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANASTROZOLE versus TESLAC.
ANASTROZOLE vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anastrozole is a selective non-steroidal aromatase inhibitor. It inhibits the conversion of androgens to estrogens in peripheral tissues, thereby reducing circulating estradiol levels. It has no intrinsic progestogenic, androgenic, or estrogenic activity.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
1 mg orally once daily
250 mg intramuscularly three times per week
None Documented
None Documented
Terminal elimination half-life: ~46 hours (range 30–60 hours). Clinically, steady-state reached after ~10 days; once-daily dosing maintains therapeutic concentrations.
Clinical Note
moderateAnastrozole + Digoxin
"Anastrozole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAnastrozole + Digitoxin
"Anastrozole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAnastrozole + Deslanoside
"Anastrozole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAnastrozole + Acetyldigitoxin
"Anastrozole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Primarily hepatic metabolism (85%): N-dealkylation, hydroxylation, and glucuronidation. Renal excretion of metabolites: ~10% unchanged drug in urine. Fecal elimination: ~10% as metabolites.
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category D/X
Category C
Aromatase Inhibitor
Aromatase Inhibitor